Suo HD - Search Results

1

Coexpression Network Analysis of Genes Related to the Characteristics of Tumor Stemness in Triple-Negative Breast Cancer.

Suo HD, Tao Z, Zhang L, Jin ZN, Li XY, Ma W, Wang Z, Qiu Y, Jin F, Chen B, Cao Y. Suo HD, et al. Biomed Res Int. 2020 Jul 11;2020:7575862. doi: 10.1155/2020/7575862. eCollection 2020. Biomed Res Int. 2020. PMID: 32766313 Free PMC article.

2

Immune-related lncRNAs as predictors of survival in breast cancer: a prognostic signature.

Ma W, Zhao F, Yu X, Guan S, Suo H, Tao Z, Qiu Y, Wu Y, Cao Y, Jin F. Ma W, et al. J Transl Med. 2020 Nov 23;18(1):442. doi: 10.1186/s12967-020-02522-6. J Transl Med. 2020. PMID: 33225954 Free PMC article.

3

MRPL13 is a Prognostic Cancer Biomarker and Correlates with Immune Infiltrates in Breast Cancer.

Tao Z, Suo H, Zhang L, Jin Z, Wang Z, Wang D, Wu M, Peng N, Zhao Y, Chen B. Tao Z, et al. Onco Targets Ther. 2020 Nov 27;13:12255-12268. doi: 10.2147/OTT.S263998. eCollection 2020. Onco Targets Ther. 2020. PMID: 33273831 Free PMC article.

4

Nomogram for predicting the risk of bone metastasis in breast cancer: a SEER population-based study.

Ye LJ, Suo HD, Liang CY, Zhang L, Jin ZN, Yu CZ, Chen B. Ye LJ, et al. Among authors: suo hd. Transl Cancer Res. 2020 Nov;9(11):6710-6719. doi: 10.21037/tcr-20-2379. Transl Cancer Res. 2020. PMID: 35117281 Free PMC article.

5

Metformin plays an antitumor role by downregulating inhibitory cells and immune checkpoint molecules while activating protective immune responses in breast cancer.

Jiang H, Suo H, Gao L, Liu Y, Chen B, Lu S, Jin F, Cao Y. Jiang H, et al. Int Immunopharmacol. 2023 May;118:110038. doi: 10.1016/j.intimp.2023.110038. Epub 2023 Mar 28. Int Immunopharmacol. 2023. PMID: 36996738

6

Potential roles of synaptotagmin family members in cancers: Recent advances and prospects.

Suo H, Xiao N, Wang K. Suo H, et al. Front Med (Lausanne). 2022 Aug 8;9:968081. doi: 10.3389/fmed.2022.968081. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36004367 Free PMC article. Review.

7

Dissymmetric pyridyl-substituted 3,5-bis(arylidene)-4-piperidones as anti-hepatoma agents by inhibiting NF-κB pathway activation.

Yao BR, Sun Y, Chen SL, Suo HD, Zhang YL, Wei H, Wang CH, Zhao F, Cong W, Xin WY, Hou GG. Yao BR, et al. Among authors: suo hd. Eur J Med Chem. 2019 Apr 1;167:187-199. doi: 10.1016/j.ejmech.2019.02.020. Epub 2019 Feb 7. Eur J Med Chem. 2019. PMID: 30771605

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7 results

Search Page

Filters